Pharmacological Treatment of Coronary Artery Disease With Recombinant Fibroblast Growth Factor-2
Michael Simons(Yale University), Nicolas A.F. Chronos(Dartmouth–Hitchcock Medical Center), M.J. Whitehouse(Dartmouth–Hitchcock Medical Center), Brian H. Annex(Augusta University), Ernesto V. Gervino(Dartmouth–Hitchcock Medical Center), Timothy D. Henry(Christ Hospital), Roger J. Laham(Beth Israel Deaconess Medical Center), James E. Udelson(Tufts Medical Center), Marilyn C. Pike(Bethesda Hospital), Thomas E. Moon(Virginia Commonwealth University Medical Center), Neal S. Kleiman(Houston Methodist), Harold L. Dauerman(University of Vermont Medical Center)
Cited by 652
Related Papers
Transcatheter Aortic-Valve Replacement with a Self-Expanding Valve in Low-Risk Patients
|New England Journal of Medicine|2019|3.6k
2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy
|Circulation|2011|2.1k
Contemporary Management of Cardiogenic Shock: A Scientific Statement From the American Heart Association
|Circulation|2017|1.8k
2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy
|Journal of the American College of Cardiology|2011|1.3k